 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Trial completion date, Trial primary completion date, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Jul 12, 2023
P1, N=18, Suspended, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
- | BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Journal, CAR T-Cell Therapy: Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy. (Pubmed Central) - Mar 14, 2023
These data implicate CD19 long-lived plasma cells as an important source for anti-HLA antibodies, a model supported by infrequent HLA sensitization in BCMA-CARTx subjects receiving previous plasma cell-targeted therapies. Thus, plasma cell-targeted therapies may be more effective against HLA antibodies, thereby enabling improved access to organ transplantation and rejection management.
- BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
CMV and HHV-6 after Chimeric Antigen Receptor (CAR)-T-Cell Immunotherapy for B-Cell Malignancies: A Prospective Study () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_901;
Pre-CARTx variables that may be associated with increased risk include multiple myeloma treated with BCMA-targeted CARTx, prior HCT, and more lines of antitumor treatments. Enrollment is ongoing to increase sample size and allow for adjusted analyses.
- BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Trial completion date, Trial primary completion date, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Jun 16, 2022
P1, N=18, Suspended, Sponsor: Fred Hutchinson Cancer Center
Enrollment is ongoing to increase sample size and allow for adjusted analyses. Trial completion date: Apr 2022 --> Sep 2025 | Trial primary completion date: Apr 2022 --> Sep 2024
- BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Stromal cell derived IL6 inhibits the extrinsic apoptotic pathway in multiple myeloma cell lines (Section 35) - Mar 9, 2022 - Abstract #AACR2022AACR_4767;
Clinical trials have shown that BCMA targeted CAR-T therapy induces MM remission in most patients with heavily pretreated relapsed refractory MM; however, the duration of the response has been disappointing...This suggests that soluble factors in the BMM can convert cells from type I to type II (mitochondrial-dependent) death receptor signaling and that inhibiting BMM signals such as IL6 may enhance FASL-induced cell death in MM. However, the data also demonstrate that the role of FAS in CAR-T killing is cell context dependent.
- Darzalex IV (daratumumab) / J&J
Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma (GWCC - Hall C2-C3) - Nov 5, 2021 - Abstract #ASH2021ASH_1989;
The median age was 65 years, and patients had received a median of 10 prior lines of therapy (range, 4-19). 67% of patients were refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, 72% had high-risk cytogenetic features, and 28% had extramedullary disease.
- BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Trial primary completion date, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Aug 18, 2021
P1, N=18, Suspended, Sponsor: Fred Hutchinson Cancer Research Center
67% of patients were refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, 72% had high-risk cytogenetic features, and 28% had extramedullary disease. Trial primary completion date: Jul 2021 --> Apr 2022
- ||| BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Trial completion date, Trial suspension, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Aug 18, 2021
P1, N=18, Suspended, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2021 --> Apr 2022 Trial completion date: Jul 2034 --> Apr 2022 | Recruiting --> Suspended
- || BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Enrollment open, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - May 1, 2020
P1, N=18, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Jul 2034 --> Apr 2022 | Recruiting --> Suspended Suspended --> Recruiting
- ||| BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Trial suspension, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Mar 31, 2020
P1, N=18, Suspended, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Recruiting Recruiting --> Suspended
- | BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Trial initiation date, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Nov 13, 2018
P1, N=18, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Suspended Initiation date: Sep 2018 --> May 2018
- | BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
Enrollment open, Trial initiation date, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2018
P1, N=18, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Sep 2018 --> May 2018 Not yet recruiting --> Recruiting | Initiation date: May 2018 --> Sep 2018
- | BCMA targeted CAR T / Fred Hutchinson Cancer Research Center
New P1 trial, Combination therapy, CAR T-Cell Therapy: NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov) - Apr 17, 2018
P1, N=18, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center